Management of Rosacea-Prone Skin: Evaluation of a Skincare Product Containing Ambophenol, Neurosensine, and La Roche-PosayThermal Spring Water as Monotherapy or Adjunctive Therapy
August 2013 | Volume 12 | Issue 8 | Original Article | 920 | Copyright © August 2013
Sophie Seité PhD,a Florence Benech PharmD,b Sandrine Berdah PhD,b Muriel Bayer PharmD,b Sophie Veyrat PharmD,b Evelyne Segot PharmD PhD,b Marcela Sakalikova Mgr,c Lucia Gibejova Mgr,c Hana Zelenkova MD PhDc
aLa Roche-Posay Pharmaceutical Laboratories, Asnières, France
bL’Oréal Research and Innovation, Chevilly Larue, France
cDOST Svidnik, Private Clinic of Dermatovenerology, Svidnik, Slovakia
In addition, the tolerance and the satisfaction with the test
formula were good to excellent in 85% and 74% of cases respectively
and in 77% of cases, patients noticed a positive
impact on their skin quality.
Evaluation of Tolerance as Adjunctive Therapy
Test formula has been also used by patients with stage 1 or stage
2 rosacea as adjunctive therapy with Metronidazole (n=181);
Azelaic acid (n=23); Erythromycin (n=14); Doxycycline (n=31); Minocyclin
(n=7); Isotretinoin (n=11); Ichtyol (n=107); Vascular laser
(n=16); IPL (n=43) with a “good to excellent” tolerance and satisfaction
in more than 80% of cases (data not shown).
Evaluation of the Efficacy Post-Prescription Treatment
Lastly, test formula was used in association with a leading rosacea
prescription medicine (Metronidazole) for 8 weeks and
for an additional 8 weeks following treatment withdrawal. After
16 weeks, the percentage of patients with global improvement
in the signs of rosacea stayed significantly higher in the group
treated with the test formula compared to the one treated
with the vehicle (Figure 4). The formula containing Ambophenol,
Neurosensine, and La Roche-Posay thermal spring water
helped prolong the efficacy of the Metronidazole treatment.
Topical agents provide the mainstay of treatment for many patients
with rosacea. The three primary drugs approved for the
topical treatment of rosacea are azelaic acid, metronidazole and
sodium sulfacetamide-sulphur.1 Their efficacy has been validated
by multiple studies. A number of other topical therapies are
used in rosacea but are not approved for the indication.1 This
also includes adapted skincare and cosmetics. We have evaluated
the test formula in association to various topical therapies
with good tolerance and satisfaction.
We have also shown that the test formula in erythro-couperosis
patients can significantly reduce redness and telangiectasia
intensity after a 1 month treatment and that this effect was prolonged
even 1 week after the end of treatment.